Search

Displaying results 5811 - 5820 of 8696 in total
  1. Drug

    Danoprevir

    go.drugbank.com/drugs/DB11779
    Investigational

    Danoprevir has been used in trials studying the treatment of Hepatitis C, Chronic.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  2. Drug

    Ethyl macadamiate

    go.drugbank.com/drugs/DB11243
    Approved

    Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.

  3. Drug

    Hydrolyzed soy protein

    go.drugbank.com/drugs/DB15607
    Investigational

    Mixtures: P3 Ai, P3 Ai
  4. Drug

    Flumequine

    go.drugbank.com/drugs/DB08972
    ApprovedWithdrawn

    Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    CRx-139

    go.drugbank.com/drugs/DB05744
    Experimental

    This novel synergistic combination is developed for the treatment of immuno-inflammatory diseases. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.

  6. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine. … It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.

  7. Drug

    EVT-101

    go.drugbank.com/drugs/DB05956
    Investigational

  8. Drug

    XP12B

    go.drugbank.com/drugs/DB04928
    Investigational

    XP12B is being developed by Xanodyne Pharmaceuticals for the treatment of menorrhagia (heavy menstrual bleeding). It was granted Fast Track status for this indication by the FDA in November 2004.

  9. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  10. Drug

    Diosmetin

    go.drugbank.com/drugs/DB11259
    Approved

    Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits [A27231]. … It also acts as a weak TrkB receptor agonist [A27230].